Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. - Wikidata - awgldk - TriplyDB

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

http://www.wikidata.org/entity/Q33149039

about

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Microtubule-binding agents: a dynamic field of cancer therapeutics.Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models Antivascular ultrasound therapy extends survival of mice with implanted melanomas A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Anti-angiogenesis therapies: their potential in cancer management A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy.Cardiovascular toxicity profiles of vascular-disrupting agents.Vascular targeting agents.Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.Combretastatin A4 phosphate: background and current clinical status.Measuring tumour vascular response to antivascular and antiangiogenic drugs.Cholesterol superlattice modulates CA4P release from liposomes and CA4P cytotoxicity on mammary cancer cells.Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog.Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.Epothilones in the treatment of cancer.Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.Vascular disrupting agents in clinical development Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents.Tumour targeting by microtubule-depolymerizing vascular disrupting agents.Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death.

P2860

Q24642049-045AF301-E5CA-4067-AE09-2BAC47BEA112 Q26751344-0FC1B2A1-FB84-478C-840F-E029680A74EC Q26781365-E58C68D1-CBD8-43BF-9F55-A4033EB4527E Q27690249-7560A767-3BF5-40B2-A4BE-DA114D691FE3 Q28268126-4A69DED9-614E-4A1B-9DBC-6C216CA41A42 Q28543671-614F26C2-BCED-4D29-8567-43B438B80FF3 Q30475723-96490C1D-CE03-4A6C-8012-3BC4B49C8367 Q33159659-E2B0EB2D-19C8-43CC-B474-46109A2CAB78 Q33265941-4FF97036-D216-428C-A387-7EA51A3A4188 Q33389126-A0B9E500-78A6-41AA-B3E4-0A93CD789F70 Q33393879-D7D953BC-0F48-4AC4-8E54-28E8D5E7F33E Q33956056-72AEF825-286F-45D7-9E0E-592E0819AA07 Q34035391-F39C9E6D-FC58-4B4E-8738-11D5B1C0BB6B Q34093032-D0D1C907-C72B-42D3-896D-C2ED8FE1EE32 Q34122191-2CF9CE4F-EACC-4817-81BB-1DBD4C155D7C Q34122854-658F5C1F-43B2-4634-B77A-BF29B51A4AE4 Q34491366-3AD822EA-FFC8-416F-BA8D-B2A87AFAF09A Q34538659-159476C0-7661-48A8-BD19-899BA13B27BF Q34546774-49C03B7F-880E-4205-9664-7EE059DAB8C8 Q34547313-3DC6BA14-1168-4D3F-8900-852ECDFAB88E Q34954063-BCBA3CDC-96ED-422F-ACC6-7C7F1F250FF0 Q35419004-2A0174F8-643D-49D5-9A7F-115D0AA45808 Q35488068-04B6F6C0-865A-4B7E-BF89-BAAD35F61E85 Q35584746-D192F565-2D26-4A40-BC79-1F6A07A1D12E Q35642613-93D1B9C2-A20C-42A7-AB77-58DA7A68FDCB Q35855949-555973CE-A20E-471B-A99E-3DB98919F91A Q35871932-E9632B1A-8505-4C7D-992A-ECB820447E87 Q35904992-F52FD334-B12D-4014-AADC-C11022A714AD Q35926144-EC02D13F-C575-4B50-B3A4-2B2B21225FCA Q36295196-55BC44F4-B840-4A05-9C7E-9E570244C846 Q36378377-B0F5C9D7-6D5E-4E7D-BFF5-2BDBFE2DC1EC Q36482522-01346E28-3F32-4B35-B342-BDFDAC88773F Q36491842-45079E8C-5F6B-4DE6-A11B-99A547FD7D94 Q36609881-5718A528-6FA7-46F3-88AA-BACCBFE5EFD6 Q36613314-D8B982EB-9324-4A28-AF5E-5F033034B4C5 Q36765436-D71C9DCD-B870-4246-AB5D-464F14FB329F Q36785948-AE78325B-91FF-47C6-8D6D-D4EC76941EEE Q36860049-314FBA49-0E7C-42B5-A497-9D9C923C6E34 Q37008845-502B87FC-2190-4A5B-8DF4-C8D132BB0328 Q37373970-B3FD0D15-9958-4564-889D-C1C2A46283DD

P2860

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

http://www.wikidata.org/entity/Q33149039

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Phase I clinical trial of week ...... l and pharmacokinetic results.

@ast

Phase I clinical trial of week ...... l and pharmacokinetic results.

@en

type

label

Phase I clinical trial of week ...... l and pharmacokinetic results.

@ast

Phase I clinical trial of week ...... l and pharmacokinetic results.

@en

prefLabel

Phase I clinical trial of week ...... l and pharmacokinetic results.

@ast

Phase I clinical trial of week ...... l and pharmacokinetic results.

@en

P1433

Q33149039-CDF79DDC-9573-4883-905A-CBA8C09821E2

P1476

Q33149039-14CFDDDA-F576-4567-80B0-447970747207

P2093

Q33149039-1496D1E1-8CFF-48AF-AD55-96CCDC9FBFFD

Q33149039-453F26C5-91CA-485E-899D-FB1AEEE3A3A4

Q33149039-4992DC1A-4D91-479B-9F97-E89B155082D0

Q33149039-7CB74E0C-9CC9-4EBB-82B3-EE657B6DEBF6

Q33149039-A5FE8592-8396-4DA4-BDE3-44C7B442CE53

Q33149039-BAEA4AB7-DE8B-4605-A1FE-4D0D4D703EE8

Q33149039-DCA3515D-FF57-4637-8BDF-2A5303091756

Q33149039-FC07F105-F849-4294-9D6C-34B804A4029A

P304

Q33149039-E142CEED-89CD-4BE9-9048-DB0148B5055A

P31

Q33149039-097A76AE-A20B-4E9D-91B2-7375EFBFB004

P356

Q33149039-E598CD64-21D3-41D2-8A3B-5827AFACD25F

P407

Q33149039-1FFC5A06-491D-4336-B0A2-1DFB2D1CF7A1

P433

Q33149039-977D30F4-E2F5-40E0-B46F-DD3D370F0E68

P478

Q33149039-FA88EA08-9C5B-4080-9609-30820EBAA8B5

P577

Q33149039-74A6059E-32AD-4B3D-82BE-2F31C85C2841

P698

Q33149039-AD8A397B-2351-4636-94FF-0B120FDA6BB6

P921

Q33149039-99D10CD9-A6F7-4004-B086-759E52473D65

P356

JCO.2003.05.185

P1433

Journal of Clinical Oncology

P1476

Phase I clinical trial of week ...... l and pharmacokinetic results.

@en

P2093

Gordon J S Rustin

http://www.w3.org/2001/XMLSchema#string

Helen Anderson

http://www.w3.org/2001/XMLSchema#string

Lindsey Gumbrell

http://www.w3.org/2001/XMLSchema#string

Lisa K Folkes

http://www.w3.org/2001/XMLSchema#string

Luiza Sena

http://www.w3.org/2001/XMLSchema#string

Michael Stratford

http://www.w3.org/2001/XMLSchema#string

Patricia M Price

http://www.w3.org/2001/XMLSchema#string

Susan M Galbraith

http://www.w3.org/2001/XMLSchema#string

P304

2815-2822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.05.185

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12807934

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial